CYP27A1
Basic information
Region (hg38): 2:218781749-218815293
Previous symbols: [ "CYP27" ]
Links
Phenotypes
GenCC
Source:
- cerebrotendinous xanthomatosis (Definitive), mode of inheritance: AR
- cerebrotendinous xanthomatosis (Strong), mode of inheritance: AR
- cerebrotendinous xanthomatosis (Strong), mode of inheritance: AR
- cerebrotendinous xanthomatosis (Supportive), mode of inheritance: AR
- cerebrotendinous xanthomatosis (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Cerebrotendinous xanthomatosis | AR | Biochemical; Cardiovascular | The condition manifests with progressive neurologic dysfunction, as well as cardiovascular and ophthalmologic dysfunction, and medical treatment (eg, with chenodeoxycholic acid and HMG-CoA reductase inhibitors) can be beneficial | Biochemical; Cardiovascular; Gastrointestinal; Neurologic; Ophthalmologic | 5636664; 5676919; 5355255; 4825231; 7315872; 7298854; 6504105; 3106810; 3128689; 1708392; 7847220; 7964884; 10430841; 11804206; 12555943; 11939886; 16278884; 18227423; 20301583; 20402754; 20450308; 20558929; 21553098; 22018287; 22336472; 23375591 |
ClinVar
This is a list of variants' phenotypes submitted to
- Cholestanol storage disease (73 variants)
- not provided (17 variants)
- CYP27A1-related disorder (2 variants)
- Cardiovascular phenotype (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CYP27A1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 272 | 278 | ||||
missense | 16 | 315 | 345 | |||
nonsense | 21 | 27 | 50 | |||
start loss | 1 | |||||
frameshift | 31 | 34 | 68 | |||
inframe indel | 7 | |||||
splice donor/acceptor (+/-2bp) | 17 | 19 | 37 | |||
splice region | 1 | 19 | 45 | 1 | 66 | |
non coding | 100 | 12 | 117 | |||
Total | 73 | 96 | 338 | 381 | 15 |
Highest pathogenic variant AF is 0.0000920
Variants in CYP27A1
This is a list of pathogenic ClinVar variants found in the CYP27A1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-218781813-T-C | Cholestanol storage disease | Uncertain significance (Jun 14, 2016) | ||
2-218781824-A-AC | Cholestanol storage disease | Benign (Oct 18, 2020) | ||
2-218781848-C-T | Cholestanol storage disease | Uncertain significance (Jun 14, 2016) | ||
2-218781978-C-A | Cholestanol storage disease | Conflicting classifications of pathogenicity (Oct 14, 2018) | ||
2-218782001-C-T | Cholestanol storage disease | Uncertain significance (Jun 14, 2016) | ||
2-218782021-C-T | Cholestanol storage disease | Uncertain significance (Jun 14, 2016) | ||
2-218782177-C-T | not specified • Cholestanol storage disease | Conflicting classifications of pathogenicity (Feb 07, 2020) | ||
2-218782183-A-G | Cholestanol storage disease | Uncertain significance (May 25, 2018) | ||
2-218782184-T-C | Cholestanol storage disease • not specified • CYP27A1-related disorder | Conflicting classifications of pathogenicity (Jan 23, 2023) | ||
2-218782184-T-TGGCTGCGCTG | Cholestanol storage disease | Pathogenic/Likely pathogenic (Dec 02, 2023) | ||
2-218782186-G-GC | Cholestanol storage disease | Pathogenic (Mar 01, 2024) | ||
2-218782191-G-A | Cardiovascular phenotype • Cholestanol storage disease | Likely benign (Jul 30, 2023) | ||
2-218782191-G-T | Cholestanol storage disease | Likely benign (Jan 16, 2023) | ||
2-218782191-GC-AA | Cholestanol storage disease | Uncertain significance (Sep 06, 2022) | ||
2-218782196-G-A | Cholestanol storage disease | Uncertain significance (Aug 10, 2022) | ||
2-218782197-C-T | Cholestanol storage disease | Likely benign (Oct 21, 2022) | ||
2-218782201-GC-G | Cholestanol storage disease | Likely pathogenic (Jun 12, 2023) | ||
2-218782202-C-T | not specified • Cholestanol storage disease • Cardiovascular phenotype • CYP27A1-related disorder | Uncertain significance (Apr 03, 2023) | ||
2-218782203-G-A | Cholestanol storage disease | Likely benign (May 20, 2021) | ||
2-218782203-G-C | Cholestanol storage disease | Likely benign (Nov 20, 2023) | ||
2-218782204-A-AG | Cholestanol storage disease | Pathogenic (Nov 15, 2023) | ||
2-218782207-C-T | Cholestanol storage disease | Likely benign (Dec 07, 2021) | ||
2-218782208-T-C | Cholestanol storage disease | Uncertain significance (Dec 21, 2023) | ||
2-218782211-G-A | Cholestanol storage disease | Uncertain significance (Jul 01, 2022) | ||
2-218782214-G-A | Cholestanol storage disease | Pathogenic/Likely pathogenic (Oct 10, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CYP27A1 | protein_coding | protein_coding | ENST00000258415 | 9 | 33545 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
5.29e-19 | 0.00315 | 125591 | 0 | 157 | 125748 | 0.000624 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.310 | 319 | 304 | 1.05 | 0.0000186 | 3416 |
Missense in Polyphen | 102 | 94.918 | 1.0746 | 1011 | ||
Synonymous | 0.294 | 126 | 130 | 0.967 | 0.00000808 | 1087 |
Loss of Function | -0.0185 | 28 | 27.9 | 1.00 | 0.00000167 | 275 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00123 | 0.00123 |
Ashkenazi Jewish | 0.00109 | 0.00109 |
East Asian | 0.000707 | 0.000707 |
Finnish | 0.000185 | 0.000185 |
European (Non-Finnish) | 0.000484 | 0.000484 |
Middle Eastern | 0.000707 | 0.000707 |
South Asian | 0.00134 | 0.00134 |
Other | 0.000489 | 0.000489 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the first step in the oxidation of the side chain of sterol intermediates; the 27-hydroxylation of 5-beta- cholestane-3-alpha,7-alpha,12-alpha-triol. Has also a vitamin D3- 25-hydroxylase activity. {ECO:0000250|UniProtKB:P17177}.;
- Disease
- DISEASE: Cerebrotendinous xanthomatosis (CTX) [MIM:213700]: Rare sterol storage disorder characterized clinically by progressive neurologic dysfunction, premature atherosclerosis, and cataracts. {ECO:0000269|PubMed:12000359, ECO:0000269|PubMed:2019602, ECO:0000269|PubMed:7915755, ECO:0000269|PubMed:9186905, ECO:0000269|PubMed:9790667}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Cholesterol metabolism - Homo sapiens (human);Primary bile acid biosynthesis - Homo sapiens (human);PPAR signaling pathway - Homo sapiens (human);27-Hydroxylase Deficiency;Bile Acid Biosynthesis;Congenital Bile Acid Synthesis Defect Type II;Cerebrotendinous Xanthomatosis (CTX);Zellweger Syndrome;Familial Hypercholanemia (FHCA);Congenital Bile Acid Synthesis Defect Type III;Vitamin D Metabolism;PPAR signaling pathway;Oxidation by Cytochrome P450;Metapathway biotransformation Phase I and II;Phase I - Functionalization of compounds;Metabolism of lipids;Endogenous sterols;Cytochrome P450 - arranged by substrate type;Biological oxidations;Metabolism;Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol;Synthesis of bile acids and bile salts via 24-hydroxycholesterol;Synthesis of bile acids and bile salts via 27-hydroxycholesterol;Synthesis of bile acids and bile salts;Bile acid and bile salt metabolism;Metabolism of steroids;Bile acid biosynthesis;C21-steroid hormone biosynthesis and metabolism;Vitamin D3 (cholecalciferol) metabolism;bile acid biosynthesis, neutral pathway
(Consensus)
Recessive Scores
- pRec
- 0.449
Intolerance Scores
- loftool
- 0.705
- rvis_EVS
- -0.31
- rvis_percentile_EVS
- 32.23
Haploinsufficiency Scores
- pHI
- 0.420
- hipred
- N
- hipred_score
- 0.146
- ghis
- 0.440
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.900
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cyp27a1
- Phenotype
- cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; liver/biliary system phenotype; renal/urinary system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); digestive/alimentary phenotype; endocrine/exocrine gland phenotype; homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- bile acid biosynthetic process;sterol metabolic process;oxidation-reduction process
- Cellular component
- mitochondrion;mitochondrial matrix;mitochondrial membrane
- Molecular function
- iron ion binding;steroid hydroxylase activity;oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen;heme binding